Chigasaki, Japan

Kuniya Sakurai


Average Co-Inventor Count = 5.4

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Kawasaki, JP (1994 - 2004)
  • Chigasaki, JP (2007 - 2010)

Company Filing History:


Years Active: 1994-2010

Loading Chart...
5 patents (USPTO):

Title: Kuniya Sakurai: Innovator in Antithrombotic Compounds

Introduction

Kuniya Sakurai is a notable inventor based in Chigasaki, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of antithrombotic agents. With a total of five patents to his name, Sakurai's work has the potential to impact therapeutic strategies for atherothrombotic diseases.

Latest Patents

Sakurai's latest patents focus on inhibitors of the GPIb-vWF interaction. These compounds are characterized by a specific formula, where R1, R2, A, B, D, E, n, m, or o have defined meanings. The compounds are recognized as valuable pharmacologically active agents. They serve as reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). Their antithrombotic effect makes them suitable for therapy and prophylaxis of atherothrombotic diseases.

Career Highlights

Throughout his career, Kuniya Sakurai has worked with prominent companies such as Ajinomoto Co., Ltd. and Sanofi-Aventis Deutschland GmbH. His experience in these organizations has contributed to his expertise in the development of innovative pharmaceutical compounds.

Collaborations

Sakurai has collaborated with notable colleagues, including Kazumi Tashiro and Takashi Kayahara. These partnerships have likely enhanced his research and development efforts in the field of pharmacology.

Conclusion

Kuniya Sakurai's contributions to the development of antithrombotic agents highlight his role as an influential inventor in the pharmaceutical industry. His innovative work continues to pave the way for advancements in the treatment of atherothrombotic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…